GETREAL developed new tools and resources for incorporating real-life data into drug development, which could increase confidence in new medicines and help to get them to patients more quickly. In an interview with the IMI Programme Office, project coordinator Elaine Irving of GlaxoSmithKline explains the main project achievements, and why they wouldn’t have been possible without IMI.
The Innovative Medicines Initiative (IMI) has launched its 100th project in the form of Hypo-RESOLVE, a 4 year, EUR 26.8 million project on diabetes. The project focuses on hypoglycaemia, which occurs when diabetes patients’ blood sugar levels become dangerously low. Despite its seriousness, little is known about hypoglycaemia; the goal of Hypo-RESOLVE is to change that.
According to the ‘obesity paradox’, it is possible to be overweight or even obese yet not have an increased risk of heart disease. Now, a study shows that in fact the risk of heart and blood vessel problems such as heart attacks, strokes, and high blood pressure, rises as body mass index (BMI) increases beyond 22-23 kg/m2. The research was funded in part by IMI through the EMIF project.
IMI’s ADVANCE project has developed a web application with an interactive dashboard designed to make it easier to monitor the benefits and risks of vaccines in near real time. The tool is described in a paper in the journal Drug Safety. Once implemented, it would allow users to rapidly determine whether further regulatory or public health actions may be needed.
IMI’s PREDECT project developed new, much-improved laboratory models of cancer, which could improve the accuracy with which pharmaceutical companies predict the effectiveness of new drugs. In an interview the IMI Programme Office, the project leaders explain the project’s most significant breakthroughs, and how these achievements will help in the future search for new drugs.
IMI's EMIF project is helping researchers tap into Europe's treasure trove of electronic health data, saving them time and money in their quest to cure and develop better drugs for debilitating diseases. The effort has already led to promising findings linked to Alzheimer's and obesity.
April 30th 2018 marks 10 years since the first IMI call for proposals. Today, our projects are delivering results in some of the most challenging areas of health research. And we think that’s worth celebrating.
IMI’s OncoTrack project developed colon cancer models which allow researchers to more accurately predict the effect of drugs on different types of colon cancer tumours. This and other project outputs are already helping some doctors in choosing the right drug for the right patient, and could lead to more effective treatments in the future.
Scientists have identified five subtypes of diabetes, a finding that will pave the way for more personalised treatments for the disease. Patients in the different groups have different risk levels for certain complications associated with diabetes, such as kidney damage and eye disease. The work was funded in part by IMI through the projects BEAT-DKD and RHAPSODY.